Question to the Department of Health and Social Care:

To ask His Majesty's Government what is the breakdown of utilisation of the Innovative Medicines Fund for (1) interim funding for medicines recommended by the National Institute for Health and Care Excellence, and (2) managed access, since June 2022.

The National Institute for Health and Care Excellence (NICE) has not yet made a recommendation for managed access under the Innovative Medicines Fund (IMF), and so the fund has been used exclusively for interim funding to accelerate patient access to medicines recommended by NICE for routine commissioning. To date, four medicines have received interim funding through the IMF.